<DOC>
	<DOCNO>NCT02437071</DOCNO>
	<brief_summary>The radiation therapy ablation patient receive standard therapy treat tumor radiate ablated . Radiation therapy ablation plus pembrolizumab might lead strong immune response may control destroy tumor receive radiation therapy ablation . The purpose study find effect , good and/or bad , pembrolizumab patient , cancer receive radiation therapy ablation .</brief_summary>
	<brief_title>Assess Efficacy Pembrolizumab Plus Radiotherapy Ablation Metastatic Colorectal Cancer Patients</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Pembrolizumab</mesh_term>
	<criteria>Be willing able provide write informed consent/assent trial . Histologically cytologically confirm CRC . Metastatic recurrent CRC Subjects receive two standard available therapy know prolong survival would consider eligible . Such therapy include regimen contain oxaliplatin irinotecan combination fluoropyrimidine appropriate ( e.g. , FOLFOX FOLFIRI variant ) . At least one tumor palliative RT consider appropriate standard therapy ( cohort 1 ) ; , least one tumor palliative ablation consider appropriate standard therapy ( cohort 2 ) . At least one index lesion undergo RT ablation , measurable base RECIST 1.1 . Be ≥ 18 year age day sign informed consent . Consent tumor biopsy blood draws research purpose . Consent use available archived tissue research purpose . Have performance status 0 1 ECOG Performance Scale . Demonstrate adequate organ function define Table 6.1 , screen lab perform within 6 week treatment initiation . Hematological Absolute neutrophil count ( ANC ) ≥1,500 /mcL Platelets ≥100,000 / mcL Renal Serum creatinine OR Measured calculated* creatinine clearance ( GFR also use place creatinine CrCl ) ≤1.5 X upper limit normal ( ULN ) OR ≥60 mL/min subject creatinine level &gt; 1.5 X institutional ULN Hepatic Serum total bilirubin ≤ 1.5 X ULN OR Direct bilirubin ≤ ULN subject total bilirubin level &gt; 1.5 ULN AST ( SGOT ) ALT ( SGPT ) ≤ 2.5 X ULN OR ≤ 5 X ULN subject liver metastasis Coagulation International Normalized Ratio ( INR ) Prothrombin Time ( PT ) ≤1.5 X ULN unless subject receive anticoagulant therapy long PT PTT within therapeutic range intend use anticoagulant Activated Partial Thromboplastin Time ≤1.5 X ULN unless subject receive anticoagulant therapy long PT PTT within therapeutic range intend use anticoagulant Creatinine clearance calculate per institutional standard . Female subject childbearing potential negative serum pregnancy within 2 week prior start radiation therapy undergoing ablation . Female subject childbearing potential willing use 2 method birth control surgically sterile , abstain heterosexual activity course study 120 day last dose study medication ( Reference Section 9.5.2 ) . Subjects childbearing potential surgically sterilize free menses &gt; 1 year . Male subject agree use adequate method contraception start first dose study therapy 120 day last dose study therapy . Is currently participate participate study investigational agent use investigational device within 4 week first dose treatment . Has diagnosis immunodeficiency receive systemic steroid therapy form immunosuppressive therapy within 7 day prior first dose trial treatment . Has prior monoclonal antibody within 4 week prior study Day 1 recover ( i.e. , ≤ Grade 1 baseline ) adverse event due agent administer 4 week earlier . Has prior chemotherapy , target small molecule therapy within 2 week prior study Day 1 recover ( i.e. , ≤ Grade 1 baseline ) adverse event due previously administer agent . ° Note : Subjects ≤ Grade 2 neuropathy exception criterion may qualify study . If subject receive major surgery , must recover adequately toxicity and/or complication intervention prior start therapy . Has know additional malignancy progress require active treatment . Exceptions include basal cell carcinoma skin , squamous cell carcinoma skin , situ cervical cancer undergone potentially curative therapy . Has know active central nervous system ( CNS ) metastases and/or carcinomatous meningitis . Subjects previously treat brain metastasis may participate provide stable ( without evidence progression image least four week prior first dose trial treatment neurologic symptom return baseline ) , evidence new enlarge brain metastasis , use steroid least 7 day prior trial treatment . Has active autoimmune disease require systemic treatment within past 3 month document history clinically severe autoimmune disease , syndrome require systemic steroid immunosuppressive agent . Subjects vitiligo resolve childhood asthma/atopy would exception rule . Subjects require intermittent use bronchodilator local steroid injection would exclude study . Subjects hypothyroidism stable hormone replacement Sjorgen 's syndrome exclude study . Has evidence interstitial lung disease active , noninfectious pneumonitis . Has active infection require systemic therapy . Has history current evidence condition , therapy , laboratory abnormality might confound result trial , interfere subject 's participation full duration trial , best interest subject participate , opinion treat investigator . Has know psychiatric substance abuse disorder would interfere cooperation requirement trial . Is pregnant breastfeeding , expect conceive father child within project duration trial , start prescreening screen visit 120 day last dose trial treatment . Has receive prior therapy antiPD1 , antiPDL1 , antiPDL2 , antiCD137 , antiCytotoxic Tlymphocyteassociated antigen4 ( CTLA4 ) antibody ( include ipilimumab antibody drug specifically target Tcell costimulation checkpoint pathway ) . Has know history Human Immunodeficiency Virus ( HIV ) ( HIV 1/2 antibody ) . Has know active Hepatitis B ( e.g. , HBsAg reactive ) Hepatitis C ( e.g. , HCV RNA [ qualitative ] detect ) . Has receive live vaccine within 30 day prior first dose trial treatment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Radiotherapy</keyword>
	<keyword>Ablation</keyword>
	<keyword>Pembrolizumab</keyword>
	<keyword>15-069</keyword>
	<keyword>Metastatic Colorectal Cancer Patients</keyword>
</DOC>